62 filings
8-K
APRE
Aprea Therapeutics Inc
10 Apr 24
IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented
4:15pm
8-K
APRE
Aprea Therapeutics Inc
26 Mar 24
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
8:15am
8-K
APRE
Aprea Therapeutics Inc
12 Mar 24
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
4:31pm
8-K
APRE
Aprea Therapeutics Inc
6 Feb 24
Other Events
5:01pm
8-K
APRE
Aprea Therapeutics Inc
2 Feb 24
Results of Operations and Financial Condition
4:26pm
8-K
8cvkmprh1naf
26 Jan 24
Entry into a Material Definitive Agreement
7:13am
8-K
fcnuwi jg261ckfii
4 Jan 24
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
4:16pm
8-K
2kstgw58
9 Nov 23
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:15pm
8-K
fddo8tzmztzu2r137
16 Oct 23
Other Events
5:29pm
8-K
bzis 30jb8
13 Oct 23
Other Events
7:31am
8-K
59mxf io9
11 Sep 23
Other Events
8:30am
8-K
pk90am
24 Aug 23
Departure of Directors or Certain Officers
8:00am
8-K
adt 5pabpdtf
10 Aug 23
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
7:36am
8-K
r4yxxadb4ony z2
5 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
8-K
o7mufln8 348u0mf7n3
15 May 23
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
12:00am
8-K
2sr6jejf
8 May 23
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
8:45am
8-K
206vp 5zm5
18 Apr 23
Changes in Registrant's Certifying Accountant
4:15pm
8-K
glup0r93lc5tk
30 Mar 23
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
4:16pm
8-K
wcp rxvu2hsh
13 Mar 23
Regulation FD Disclosure
6:02am
8-K
wm8s6eo3wd2n
1 Mar 23
Other Events
5:16pm